anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Arm 1: Hydroxychloroquine 400mg orally twice a day for one day, followed by 200mg twice a day for four consecutive days (Five days in total). The drug will be supplied in 200mg tablets.
The present invention relates to a cosmetic composition for ameliorating skin wrinkles and moisturizing skin containing a Stachys japonica Miq. extract which is fermented by mycelium of Lentinus lepideus. According to the present invention, the Stachys japonica Miq. extract exhibits excellent antioxidant functions, suppresses production of matrix metalloproteinase-1 (MMP-1), and enhances collagen synthesis. Accordingly, the cosmetic composition produced by using the Stachys japonica Miq. extract fermented by mycelium of Lentinus lepideus can bring excellent moisturizing effects as well as wrinkle amelioration effects.
This study is a randomized controlled trial in which 40 adolescent girls aged 12-17 years-old with weight in the 75th percentile or higher for their age and sex, and elevated anxiety symptoms, will be randomly assigned to an IPT or CBT 12-week group intervention. Approximately 20 adolescent girls will be enrolled at each of two sites: Uniformed Services University (USU) and Colorado State University (CSU). After a screening and baseline assessment, participants will attend an individual meeting with the leaders of their assigned group to learn more about the group process and establish goals. They will then participate in the group program for 12 consecutive weeks. Each group will be led by a PhD-level clinical psychologist and a healthcare trainee. In-person and remote assessments, will be conducted at baseline, in the \~two weeks post-intervention (i.e., 12-week follow-up), and at 1, 2, and 3 years post-intervention. These assessments will consist of body measurements, blood draws for collection markers of metabolic functioning, and surveys and interviews of psychological and social functioning. At baseline, two weeks, and one year post-intervention, participants will also have a week-long period during which they will wear devices collecting activity and physiological data, and complete phone surveys assessing disinhibited eating behaviors, food craving, affect, cognitions, and avoidance behaviors.
PURPOSE:To obtain the subject plaster effective in suppressing and ameliorating various symptoms caused by gingivitis and pyorrhea when directly applied to the diseased part in the oral cavity, including lysozyme chloride in combination with allantoin and hinokitiol in a water-soluble film. CONSTITUTION:A water-soluble film containing allantoin, etc., is incorporated with 0.2-20pts.wt. of lysozyme chloride to obtain the objective plaster. Lysozyme chloride is an anti-inflammatory enzymatic agent having lysing action to bacteria, anti-inflammatory action against carrageenin edema, tissue- restoration action, hemostatic action, etc., and exhibits its effect for the prevention of periodontosis and the inhibition of the progress of the disease. The water-soluble film is a film dissolving in the oral cavity or stomach (e.g. polyvinyl pyrrolidone or gelatin film) or an enteric film (e.g. hydroxypropyl methylcellulose acetate succinate). It is used in the form of a laminated film, etc., having a thickness of 20-300mum.
Enteroviruses have been shown to cause mesangioproliferation and glomerulonephritis in mice (especially coxsackievirus B4). In some cases, large amounts of IgA are deposited in the mesangium, resembling human IgA-nephropathy. In humans, case reports indicate the propensity of certain enteroviruses to cause kidney infections.

Our project aims to analyze urine of children with suspected enteroviral infections (e.g. meningitis, myocarditis, sepsis of the newborn etc.) to identify cases suspicious of concomitant enteroviral kidney affection. To achieve this aim, enterovirus-PCRs will be performed and microhematuria searched for.
Disclosed are water-dispersible fibers derived from sulfopolyesters having a Tg of at least 25° C. The fibers may contain a single sulfopolyester or a blend of a sulfopolyester with a water-dispersible or water-nondispersible polymer. Also disclosed are multicomponent fibers comprising a water dispersible sulfopolyester having a Tg of at least 57° C. and a water non-dispersible polymer. The multicomponent fibers may be used to produce microdenier fibers. Fibrous articles may be produced from the water-dispersible fibers, multicomponent fibers, and microdenier fibers. The fibrous articles include water-dispersible and microdenier nonwoven webs, fabrics, and multilayered articles such as wipes, gauze, tissue, diapers, panty liners, sanitary napkins, bandages, and surgical dressings. Also disclosed is a process for water-dispersible fibers, nonwoven fabrics, and microdenier webs. The fibers and fibrous articles have further applications in flushable personal care and cleaning products, disposable protective outerwear, and laminating binders.
Patients undergo collection of bone marrow samples prior to sirolimus dosing on day 4 and within 1 week and no later than day 45 of hematologic recovery. Patients receive sirolimus PO on days 2-9 (loading dose on day 1 only), and standard MEC chemotherapy comprising mitoxantrone hydrochloride IV over 15 minutes, etoposide IV over 1 hour, and cytarabine IV over 1 hour every 24 hours on day 4-8.
Our language affects patients' perceptions of therapies. In Parkinson's disease, emergent response fluctuations and dyskinesias typically trigger conversations around commencing an "Advanced Therapy" which carries notions of Advanced Disease. The patient, resolute in their commitment to fighting the disease, is misled. Chasing reassurance that their disease has not yet progressed considerably; they may therefore resist a potentially life-changing therapy. Instead, we should offer a "Smart Therapy". This term more accurately and positively describes therapies on offer that stabilize response fluctuations and improve quality of life, without a focus on the negative connotations of progression to more advanced disease.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to galenic compositions for oral administration providing the enhanced absorption of substance that act in digestive tract by trans-membrane or para-cellular way that exhibit hydrophilic or ionizing properties in physiological media. Composition comprise at least one active substance, absorption-enhancing agent with a value of hydrophilic-lipophilic balance above 8. This absorption-enhancing agent comprises one or some lipid compounds taken among group including polysorbates, polyoxyethylene and alkyl ethers, polyoxyethylene and fatty acid esters, fatty acids, saturated alcohols, bile acid and their salts with pharmaceutically acceptable cations,  -alcanol and fatty acid esters, polyol and fatty acid esters wherein polyol comprises from 2 to 6 hydroxyl functionally active group and polyglycosylated glycerides in combination with one or some pharmaceutically acceptable excipients. Invention relates to application of absorption-stimulating agent in preparing galenic compositions. Invention relates to a method for preparing galenic composition by wetting granulation of active substance and excipients and pressing being an active substance is used at the granulation stage as wetting liquid. Invention provides realization of indicated designation. EFFECT: valuable medicinal and pharmaceutical properties of galenics. 15 cl, 13 tbl, 9 dwg, 21 ex
The present invention relates to the ex vivo differentiation of NK cells from CD34 +  hematopoietic stem cells. Such NK cells and their progenitor cells can be used in therapies of a broad range of malignancies. In the present invention it is shown that IL-12 modulates ex  vivo  NK cell differentiation. Specific, we achieved significantly higher expression of KIR, CD16 and CD62L in the presence of IL-12 in the cell culture system. The induction of receptor expression by IL-12 occurred predominantly on an augmented population of CD33+NKG2A+ NK cells early during NK cell differentiation. These cells further show enhanced cytolytic activity against MHC class I positive AML targets. In line with the enhanced CD16 expression, IL-12 modulated ex  vivo  generated NK cells exhibit an improved antibody-dependent-cytotoxicity, using anti CD20 antibody on various B cell targets. Additional to the enhanced expression of CD62L, we show that this cell population consists of a specific chemokine receptor profile. By showing an increased capacity for adhesion to lymphendothelial cells and a specific chemokine receptor profile, we show that IL-12 provided the ex vivo generated NK cells with specific tissue-homing abilities.
PRIMARY OBJECTIVES: I. Differences in "tingling" and "numbness" (measured on 0-10 numeric rating scale; as measured by NPSI) between treated and untreated extremities at conclusion of paclitaxel therapy). SECONDARY OBJECTIVES: I. Differences in nail toxicity between treated and untreated extremities as measured by NCI-CTC v4.0 from baseline to conclusion of taxane therapy and at each time point (after each infusion and at conclusion of taxane therapy). II. Differences in peripheral sensory neuropathy subscale of NCI-CTC v 4.0 between treated and untreated extremities at each time point (after each infusion and at conclusion of paclitaxel therapy). III. Differences in pain intensity (0-10 from BPI) between treated and untreated extremities at each time point (after each infusion and at conclusion of paclitaxel therapy). IV. Differences in quantitative sensory testing between treated and untreated extremities at each time point (after each infusion and at conclusion of paclitaxel therapy). OUTLINE: Patients are randomized to 1of 2 treatment arms. ARM I. Patients wear an Elasto-Gel cold glove and sock on their dominant hand and foot every two weeks on days the patient is scheduled for paclitaxel.The glove and sock is worn for 15 minutes prior to paclitaxel infusion, 3 hours during treatment, and for 15 minutes after completion of chemotherapy for a total of 210 minutes. ARM II: Patients wear an Elasto-Gel cold glove and sock on their non-dominant hand and foot every two weeks on days the patient is scheduled for paclitaxel. The glove and sock is worn for 15 minutes prior to paclitaxel infusion, 3 hours during treatment, and for 15 minutes after completion of chemotherapy for a total of 210 minutes. In both arms, treatment repeats every 2 weeks for 4 courses in the absences of unacceptable toxicity.
PROBLEM TO BE SOLVED: To obtain the subject composition capable of retaining a perfume ingredient and humectant effects for a long period and excellent in stability of degree of clouding by including a compound including a perfume ingredient and jojoba oil (oil of Simmodsia Chinensis) as a humectant in cyclodextrin and titanium oxide as a closing agent. SOLUTION: This composition contains (A) a compound including a perfume ingredient (e.g. lemon oil) and jojoba oil as a humectant in cyclodextrin, (B) titanium oxide as a clousihng agent (preferably having a fine particulate type titanium oxide having 0.1-0.15 μm particle diameter, more preferably superfine particulate type titanium oxide having 0.2-0.05 μm particle diameter). The ratio of the perfume ingredient and jojoba oil to the cyclodextrin is preferably (1:1) to (1:10) and the ratio of the ingredient B to the ingredient A is preferably (1:0.5) to (1:15). The amounts of the ingredients based on 100 pts.wt. of the bathing agent are preferably 2-8 pts.wt. of the ingredient A and 10-30 pts.wt. of the ingredient B.
Living kidney donation has become an important source for kidney transplantation because of insufficient numbers of post mortem kidney donations. To reduce the surgical trauma of the donor operation and improve postoperative recovery minimal invasive techniques have developed. Especially the laparoscopic and the hand-assisted laparoscopic technique gained wide popularity. Minimal invasive open techniques have had less publicity. One of those open techniques is to perform the open donornephrectomy by means of an anterolateral approach. A transverse subcostal incision of 10 cm or less is made. The abdominal wall is opened by splitting the muscles and sparing the nerves. Staying in the retroperitoneal space the kidney is freed and taken out. Laparoscopic approaches have especially become more popular after the hand-assisted technique had developed. By means of an 8 cm transverse suprapubic skin incision and a vertical midline fascia incision the abdominal cavity is opened and a hand is inserted in the abdomen through an air tight sleeve. Three more trocarts are needed for the insufflation, the video camera and surgical instruments to perform a transperitoneal donornephrectomy. The hand in the abdomen assisting in the procedure has especially increased the sense of safety compared to the full laparoscopic technique without compromising the advantages of the laparoscopic technique.

So far no prospective or retrospective study has been done comparing the hand-assisted laparoscopic with the mini-incision muscle-splitting technique. Most studies that have been done comparing the (hand-assisted) laparoscopic technique with more invasive open techniques resulted in favour of the former technique.

Comparison(s): The study compares the effects of hand-assisted laparoscopic and mini-incision muscle-splitting donornephrectomy on living kidney donors.
OBJECTIVE: To evaluate the impact of extensive vaginal pelvic reconstruction surgery (PRS) on advanced pelvic organ prolapse (POP) patients with bladder outlet obstruction (BOO).
METHODS: We conducted a single-center, retrospective analysis of women who received extensive vaginal pelvic reconstruction surgery for advanced POP (POP-Q ≥3) with BOO from January 2006 to January 2016. Data regarding preoperative evaluation, surgical procedure, and postoperative management were abstracted from medical records. Patients were considered to have BOO when detrusor pressure at maximum flow (Dmax) was ≥20 cm H2O and peak flow rate (Qmax) was ≤15 mL/s. Patients with postoperative value of Dmax lower than 20 cm H2O or Qmax higher than 15 mL/s were regarded as objectively cured.
RESULTS: A total of 1894 patients with POP stages III or IV were assessed. The incidence of BOO was 22.8% (431/1894) within this patient population of advanced POP. One year after the vaginal PRS, the objective cure rate of BOO was 98.1%. Urodynamic parameters showed a significant increase in Qmax (P < 0.001), while Dmax (P < 0.001) and postvoid residual urine (PVR) (P < 0.001) were significantly decreased. Previous POP surgery, native tissue repair (NTR), PVR ≥200 mL, and maximal cystometric capacity (MCC) ≥500 mL increase the likelihood of persistent BOO in patients.
CONCLUSION: Vaginal PRS demonstrated effectiveness in treating BOO in patients with advanced POP. Irrespective of the types of transvaginal mesh (TVM), using TVM achieved better outcome than did NTR. Previous POP surgery, preoperative PVR ≥200 mL, and MCC ≥500 mL were the risk factors predicting the failure of PRS in improving BOO.
As per Protocol Amendment 8 (August 2011), the dose 40 mg TID in the medium dose treatment group was discontinued. Subjects who were receiving this dose and continued in the study were requested to down titrate.
OBJECTIVES: The aims of this study were to investigate analgesic effects of vagus nerve stimulation (VNS) on visceral hypersensitivity (VH) in a rodent model of functional dyspepsia (FD) and to compare invasive VNS with noninvasive auricular VNS (aVNS).
MATERIALS AND METHODS: Eighteen ten-day-old male rats were gavaged with 0.1% iodoacetamide (IA) or 2% sucrose solution for six days. After eight weeks, IA-treated rats were implanted with electrodes for VNS or aVNS (n = 6 per group). Different parameters, varying in frequency and stimulation duty cycle, were tested to find the best parameter based on the improvement of VH assessed by electromyogram (EMG) during gastric distension.
RESULTS: Compared with sucrose-treated rats, visceral sensitivity was increased significantly in IA-treated "FD" rats and ameliorated remarkably by VNS (at 40, 60, and 80 mm Hg; p ≤ 0.02, respectively) and aVNS (at 60 and 80 mm Hg; p ≤ 0.05, respectively) with the parameter of 100 Hz and 20% duty cycle. There was no significant difference in area under the curve of EMG responses between VNS and aVNS (at 60 and 80 mm Hg, both p > 0.05). Spectral analysis of heart rate variability revealed a significant enhancement in vagal efferent activity while applying VNS/aVNS compared with sham stimulation (p < 0.01). In the presence of atropine, no significant differences were noted in EMG after VNS/aVNS. Naloxone blocked the analgesic effects of VNS/aVNS.
CONCLUSIONS: VNS/aVNS with optimized parameter elicits ameliorative effects on VH, mediated by autonomic and opioid mechanisms. aVNS is as effective as direct VNS and has great potential for treating visceral pain in patients with FD.
BACKGROUND: Ureteral stricture (US) is a pathological stenosis in the urinary tract characterized by increased collagen synthesis and inflammation. Autophagy activation has been shown to ameliorate tissue fibrosis and protect against fibrotic diseases. Verapamil has beneficial therapeutic benefits on fibrotic disorders. The pharmacological effects of verapamil on fibroblast autophagy in US and the underlying mechanism need to be investigated further.
METHODS: US patients were recruited to isolate scar tissues, hematoxylin-eosin (HE) and Masson trichrome staining were performed to analyze histopathological changes. The US animal model was established and administered with verapamil (0.05 mg/kg) in the drinking water. Transforming growth factor (TGF)-β1 was adopted to facilitate collagen synthesis in fibroblasts. The mRNA and protein expressions were examined by qRT-PCR, western blot, immunofluorescence and immunohistochemistry. ELISA was adopted to measure interleukin (IL)-1β and IL-6 levels. Molecular interaction experiments like dual luciferase reporter and chromatin immunoprecipitation (ChIP) assays were performed to analyze the interaction between signal transducers and activators of transcription 3 (STAT3) and RNA polymerase II associated factor 1 (PAF1).
RESULTS: Herein, our results revealed that verapamil activated TGF-β1-treated fibroblast autophagy and inhibited inflammation and fibrosis by repressing Ca2+⁄calmodulin-dependent protein kinase II (CaMK II) δ-mediated STAT3 activation. Our following tests revealed that STAT3 activated PAF1 transcription. PAF1 upregulation abrogated the regulatory effect of verapamil on fibroblast autophagy and fibrosis during US progression. Finally, verapamil mitigated US in vivo by activating fibroblast autophagy.
CONCLUSION: Taken together, verapamil activated TGF-β1-treated fibroblast autophagy and inhibited fibrosis by repressing the CaMK IIδ/STAT3/PAF1 axis.
The safety and efficacy of CCT301-38 will be evaluated for subjects with AXL positive but ROR2 negative biopsy in a standard 3+3 dose escalation approach. 3 CAR T dosage will be tested in this study: 1×10\^5/kg, 1×10\^6/kg, 1×10\^7/kg CAR+ T cells.
Cognitive motor dissociation (CMD) is characterized by a dissociation between volitional brain responses and motor control, detectable only through techniques such as electroencephalography (EEG) and functional magnetic resonance imaging. Hence, it has recently emerged as a major challenge in the assessment of patients with disorders of consciousness. Specifically, this review focuses on the prognostic implications of CMD detection during the acute stage of brain injury. CMD patients were identified in each diagnostic category (coma, unresponsive wakefulness syndrome/vegetative state, minimally conscious state minus) with a relatively similar prevalence of around 20%. Current knowledge tends to indicate that the diagnosis of CMD in the acute phase often predicts a more favorable clinical outcome compared with other unresponsive non-CMD patients. Nevertheless, the review underscores the limited research in this domain, probably at least partially explained by its nascent nature and the lack of uniformity in the nomenclature for CMD-related disorders, hindering the impact of the literature in the field.
PURPOSE: To obtain perfumed water alleviating irritation to skin, having improved flavor and aroma, comprising a sterol prepared from shellfish meat as an active ingredient. CONSTITUTION: Shellfish meat such as pearl oyster is ground and dried. Lipid is extracted with an organic solvent and the organic solvent is removed from the extracted solution. The extract is saponified, extracted with ether, the ether is removed from the ether extracted solution to give an extract, which is reprecipitated with a lower alcohol. The prepared sterol is used as an active ingredient and mixed with water, ethanol and a perfume to prepare perfumed water. The perfumed water can be prepared into eau de cologne, eau de toilette, eaude de perfume and paste perfume. The role of sebum is supplied, function of skin is raised and moisture retention and body protecting function are increased by blending a cosmetic with the sterol of the shellfish meat.
A complex of a cyclodextrin and an alkane, alkene, alkyne, aromatic compound, etc. can be prepared according to the method of the present invention. These complexes can be delivered to prokaryotic and eukaryotic cells, tissues, and organs in vitro and in vivo. In this manner, the toxic, genotoxic, and mitogenic effects of these compounds can be determined. Ternary complexes further including one or more biologically active molecules in addition to an alkane, etc. can be employed to determine the modulatory effects of such biologically active molecules on these alkanes, etc.
Hair follicle development and hair growth are regulated by multiple factors and multiple signalling pathways. The hair follicle, as an important skin appendage, is the basis for hair growth, and it has the functions of safeguarding the body, perceiving the environment and regulating body temperature. Hair growth undergoes a regular hair cycle, including anagen, catagen and telogen. A small amount of physiological shedding of hair occurs under normal conditions, always in a dynamic equilibrium. Hair loss occurs when the skin or hair follicles are stimulated by oxidative stress, inflammation or hormonal disorders that disrupt the homeostasis of the hair follicles. Numerous researches have indicated that oxidative stress is an important factor causing hair loss. Here, we summarize the signalling pathways and intervention mechanisms by which oxidative stress affects hair follicle development and hair growth, discuss existing treatments for hair loss via the antioxidant pathway and provide our own insights. In addition, we collate antioxidant natural products promoting hair growth in recent years and discuss the limitations and perspectives of current hair loss prevention and treatment.
At least one compound of the formula I, in which the substituents R<1>, R<2>, R<3>, R<4> and R<5> have the meanings given in Patent Claim 1, is added as sweetening agent to the substance to be sweetened. A mixture of such compounds or a combination of at least one compound of the formula I with a solid or liquid extender or carrier can also be used. The compounds of the formula I are derivatives of sucrose, but are much sweeter than sucrose although they are comparable to it with respect to quality, and they are comparable to saccharin with respect to the intensity of the sweetening action. The method is suitable both for sweetening foodstuffs and also luxury foods, stimulants and drugs. The compounds of the formula I are not absorbed by the human body and do not have any disadvantageous action on the human organism in the widest range of conventional use concentrations. <IMAGE>